GoodRx (GDRX) Expected to Announce Earnings on Thursday

GoodRx (NASDAQ:GDRX) will likely be announcing its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $199.73 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

GoodRx Trading Up 0.6 %

Shares of GoodRx stock opened at $4.84 on Tuesday. GoodRx has a fifty-two week low of $4.09 and a fifty-two week high of $9.26. The firm has a market cap of $1.84 billion, a PE ratio of -161.33, a P/E/G ratio of 2.46 and a beta of 1.28. The business’s fifty day moving average is $4.67 and its two-hundred day moving average is $5.79. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on GDRX shares. Morgan Stanley reduced their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Barclays reduced their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Mizuho started coverage on GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price on the stock. Citigroup cut their target price on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research report on Friday, January 10th. Finally, KeyCorp cut their target price on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.38.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.